8-K: Bausch Health Appoints New CFO and EVP, US Pharma, Bolstering Leadership Team

Bausch Health has appointed Jean-Jacques Charhon as its new Chief Financial Officer and Aimee Lenar as Executive Vice President, US Pharma, effective August 19, 2024 and July 15, 2024 respectively.

Summary

• Bausch Health has appointed Jean-Jacques Charhon as Executive Vice President and Chief Financial Officer, effective August 19, 2024.
• John S. Barresi, the interim CFO, will return to his role as Senior Vice President, Controller and Chief Accounting Officer.
• Mr. Charhon's employment agreement includes a $700,000 annual base salary, a 60% target bonus, and $3,000,000 in targeted equity grants for 2025.
• He will also receive a $300,000 sign-on bonus and $3,500,000 in sign-on equity grants.
• Aimee Lenar has been appointed as Executive Vice President, US Pharma, effective July 15, 2024.
• Ms. Lenar will lead Salix Pharmaceuticals, Bausch Health's gastroenterology business, as well as Neurology, Generics, Market Access and Commercial Operations.
• Mr. Barresi will receive a one-time retention award of $350,000 in restricted stock units.
• Mr. Barresi's enhanced severance terms have been extended through December 31, 2025, and his bi-weekly stipend will continue until September 30, 2024.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting new leadership appointments and retention efforts. However, there are some costs associated with these changes.

Positives

• The appointment of a permanent CFO provides stability and leadership to the finance function.
• The hiring of Aimee Lenar as EVP, US Pharma, brings significant experience in the pharmaceutical industry.
• The retention award for John Barresi acknowledges his contributions and ensures continuity.
• The extension of Mr. Barresi's enhanced severance terms provides additional security.

Negatives

• The company will incur significant one-time costs related to the sign-on bonuses and equity grants for the new CFO.
• The company will incur additional costs related to the retention award for the interim CFO.

Risks

• There is a risk that the new CFO may not perform as expected.
• There is a risk that the new EVP, US Pharma may not be able to successfully integrate into the company.
• The company is subject to risks and uncertainties discussed in its filings with the SEC and Canadian Securities Administrators.

Future Outlook

The company's forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

Management Comments

• CEO, Thomas J. Appio, stated that Jean-Jacques Charhon and Aimee Lenar are proven leaders bringing extensive experience and expertise to their respective roles.
• The CEO thanked John Barresi for his hard work and dedication as interim CFO and stated that he is an integral part of the Financial Leadership Team.

Industry Context

The appointment of a new CFO and EVP, US Pharma, is a common practice for companies seeking to strengthen their leadership teams and drive growth. The experience of the new executives in the pharmaceutical and healthcare industries is relevant to Bausch Health's business.

Comparison to Industry Standards

• The compensation package for the new CFO, including base salary, bonus, and equity grants, is generally in line with industry standards for executive-level positions at similar-sized pharmaceutical companies.
• The one-time sign-on bonus and equity grants are also common practices to attract top talent.
• The retention award for the interim CFO is a standard practice to ensure continuity and acknowledge contributions during a transition period.
• Companies such as AbbVie, Allergan, and Galderma are comparable in terms of the pharmaceutical industry and executive compensation practices.

Management Changes

Stakeholder Impact

• Shareholders may view the new appointments positively, as they bring experience and expertise to the company.
• Employees may be impacted by the changes in leadership, but the retention of John Barresi provides some stability.
• Customers and suppliers may not be directly impacted by these changes.

Next Steps

• Jean-Jacques Charhon will assume his role as CFO on August 19, 2024.
• The company will file the employment agreement with Mr. Charhon as an exhibit to the quarterly report on Form 10-Q for the fiscal period ending September 30, 2024.

Key Dates

Keywords

Chief Financial Officer, Executive Vice President, CFO, Bausch Health, Leadership, Pharmaceuticals, Finance, Executive Team, Compensation, Retention